False Positive Paradox Calculator
Estimate the probability that a positive test result is a true positive after accounting for prevalence, sensitivity, and specificity.
Test assumptions
Required. Use a dot for decimals; enter a value from 0 to 100.
Required. The true-positive rate: how often the test is positive when the condition is present.
Required. The true-negative rate: how often the test is negative when the condition is absent.
Live result
Probability the condition is truly present given a positive test result.
Illustrative positive-result breakdown
| Outcome | Expected per 10,000 tested | Share of positive results |
|---|---|---|
| True positives | 98.00 | 33.11% |
| False positives | 198.00 | 66.89% |
| All positive results | 296.00 | 100.00% |
Among positive results
How to use this false positive paradox calculator
What this calculator does. This calculator estimates the Positive predictive value (PPV): the probability that the condition is actually present after a positive test result, given the population Base rate (prevalence), the test's Sensitivity, and its Specificity. It is a Bayes-theorem probability model, not a diagnosis and not a substitute for a test's official instructions or professional interpretation. The NCBI primer on screening performance measures explains why predictive values depend on prevalence as well as sensitivity and specificity.
When to use it. Use the model when you want to understand why a seemingly accurate test can still produce many false positives for a rare condition; when comparing how two possible specificity values affect the credibility of a positive result; when teaching base-rate effects and Bayes' theorem; or when checking a published sensitivity, specificity, and prevalence combination before discussing predictive value. It is especially useful for seeing why PPV can be much lower than sensitivity.
How to calculate. The calculator opens with a complete demonstration: 1% prevalence, 98% sensitivity, and 98% specificity. The displayed PPV and the immediately available Excel workbook use those same values. To run your own case:
- Replace Base rate (prevalence) with the relevant pre-test prevalence for the population being considered.
- Enter the test's Sensitivity and Specificity as percentages from 0 to 100. Use a dot for decimals, such as 99.5; commas and scientific notation are intentionally rejected to avoid ambiguous parsing.
- Read Positive predictive value (PPV) first, then use False-positive share, Positive-test rate, the illustrative table, and the chart to understand where positive results come from.
- Select Download Excel to export the current validated inputs and results as a real XLSX workbook. Reset clears the demonstration and calculated state; after reset, Excel export remains unavailable until all three required inputs form a complete valid case again.
Input guide. Base rate (prevalence) is a required percentage from 0% to 100% representing the share of the tested population that actually has the condition before the test result is known. The startup example is 1%. Lowering prevalence usually lowers PPV because a much larger unaffected population can generate false positives. A common mistake is substituting an individual's post-test risk for the population's pre-test rate. Sensitivity is a required percentage from 0% to 100%; the example is 98%. It is the true-positive rate, so higher sensitivity increases the true-positive contribution, but it cannot by itself eliminate false positives caused by imperfect specificity. Specificity is also required from 0% to 100%; the example is 98%. It is the true-negative rate. Its complement, 1 – specificity, is the false-positive rate among people without the condition. With low prevalence, small changes in specificity can materially change PPV because the unaffected group is large. The FDA guidance on diagnostic-test performance defines sensitivity, specificity, prevalence, and predictive value using the standard 2×2 test table.
Output guide. Positive predictive value (PPV) is the main percentage estimate: true-positive probability conditional on a positive result. A low PPV means a positive result is often false within the assumptions entered; a high PPV means positives are more often true. False-positive share is exactly 100% minus PPV and measures the share of all positive results expected to come from people without the condition. Positive-test rate is the total expected positive results divided by everyone tested, combining true positives and false positives. The header pills labeled Base rate, Sensitivity, and Specificity simply mirror the three current assumptions so you can check them at a glance.
The table uses the columns Outcome, Expected per 10,000 tested, and Share of positive results. Its True positives row is prevalence × sensitivity scaled to 10,000; False positives is (1 – prevalence) × (1 – specificity) scaled to 10,000; and All positive results is their sum. The chart uses the same two series, True positives and False positives, so its segment sizes must match the table's shares. The 10,000 scale is illustrative rather than a sample-size assumption: it changes counts, not the percentages.
Worked example. With 1% prevalence, 98% sensitivity, and 98% specificity, the true-positive contribution is 0.01 × 0.98 = 0.0098, or 98 expected true positives per 10,000 people. The false-positive contribution is 0.99 × 0.02 = 0.0198, or 198 expected false positives per 10,000. Total positives are 0.0296 of the population, or 296 per 10,000. PPV is 0.0098 ÷ 0.0296 = 0.331081..., displayed as 33.11%. The false-positive share is therefore 66.89%, while the overall positive-test rate is 2.96%. This is the counterintuitive base-rate effect: 98% sensitivity and specificity do not imply that a positive result has a 98% chance of being correct.
Learn more. For a practical example of how prevalence changes predictive value, the CDC guidance on rapid influenza diagnostic testing describes how PPV falls and false-positive results become more likely when disease prevalence is low.
Why the paradox happens
Sensitivity asks a conditional question among people who truly have the condition, while specificity asks a conditional question among people who do not. PPV asks a different conditional question: among everyone who tested positive, how many truly have the condition? When prevalence is low, the unaffected population can be far larger than the affected population. Even a small false-positive rate applied to that large unaffected group can therefore produce more false positives than true positives. This is why the base rate belongs in the calculation rather than being treated as background information.
Specificity often has a particularly strong effect in rare-condition settings because false positives equal (1 – specificity) multiplied by the large condition-absent group. The FDA home-use testing glossary defines a false positive as a result that incorrectly indicates a condition is present. In real use, test interpretation can also depend on intended population, timing, confirmatory testing, clinical features, and uncertainty in the published performance estimates. Those issues are outside this simple three-input probability model.